Principia Biopharma, Inc.
(NASDAQ : PRNB)

( )
PRNB PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.13%144.390.7%$931.31m
PFEPfizer Inc. -0.69%36.000.9%$916.30m
MRKMerck & Co., Inc. -0.37%82.630.7%$702.21m
ABBVAbbVie, Inc. -1.65%87.141.9%$652.09m
BMYBristol-Myers Squibb Co. 0.39%58.991.0%$610.21m
LLYEli Lilly & Co. -0.01%149.851.1%$556.42m
AZNAstraZeneca Plc 0.42%55.671.2%$250.47m
NVSNovartis AG -1.65%87.450.2%$165.27m
GSKGlaxoSmithKline Plc -0.54%37.800.2%$103.18m
PRNBPrincipia Biopharma, Inc. -0.05%99.950.0%$95.66m
NVONovo Nordisk A/S 0.49%69.400.1%$57.02m
SNYSanofi 1.50%50.610.2%$48.66m
RGENRepligen Corp. -1.10%142.387.1%$48.23m
OPKOPKO Health, Inc. -5.28%3.0511.2%$44.94m
RPRXRoyalty Pharma Plc 0.14%41.780.2%$44.38m

Company Profile

Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA.